Lead Product(s): Lenzilumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 27, 2020
Aji Bio Pharma will provide drug product aseptic fill finish services for Humanigen. Lenzilumab, Humanigen’s Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody is being administered as part of a Phase III study for COVID-19 patients.